Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Sarepta Therapeutics (SRPT)
Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,899,108
  • Shares Outstanding, K 93,547
  • Annual Sales, $ 933,010 K
  • Annual Income, $ -703,490 K
  • 60-Month Beta 1.02
  • Price/Sales 8.47
  • Price/Cash Flow N/A
  • Price/Book 9.95
Trade SRPT with:

Options Overview Details

View History
  • Implied Volatility 36.02% ( -6.91%)
  • Historical Volatility 144.52%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 247.47% on 10/20/23
  • IV Low 36.02% on 12/01/23
  • Put/Call Vol Ratio 4.44
  • Today's Volume 5,591
  • Volume Avg (30-Day) 9,454
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 130,056
  • Open Int (30-Day) 158,597

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.40
  • Number of Estimates 8
  • High Estimate 0.31
  • Low Estimate -2.25
  • Prior Year -1.24
  • Growth Rate Est. (year over year) +67.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.69 +11.56%
on 11/02/23
85.94 -1.75%
on 11/20/23
+7.92 (+10.35%)
since 11/01/23
3-Month
55.25 +52.83%
on 10/31/23
125.00 -32.45%
on 10/12/23
-38.07 (-31.08%)
since 09/01/23
52-Week
55.25 +52.83%
on 10/31/23
159.89 -47.19%
on 05/15/23
-38.54 (-31.34%)
since 12/01/22

Most Recent Stories

More News
3 Monster Stocks in the Making

These stocks could grow much larger over the next few years.

BEAM : 29.57 (+5.31%)
CRSP : 68.65 (+2.88%)
SRPT : 84.44 (+3.89%)
Is Sarepta Therapeutics Stock a Bad-News Buy?

Analysts still expect some sizable returns from the stock.

SRPT : 84.44 (+3.89%)
1 Gene Therapy Stock to Buy and Hold for the Long Haul

The biotech has what it takes to overcome recent obstacles.

SRPT : 84.44 (+3.89%)
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?

Just because a stock is "on sale" doesn't inherently make it worth purchasing.

LSCC : 60.26 (+2.92%)
ALGN : 220.45 (+3.11%)
SEDG : 82.48 (+3.91%)
SRPT : 84.44 (+3.89%)
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript

SRPT earnings call for the period ending September 30, 2023.

SRPT : 84.44 (+3.89%)
Sarepta Therapeutics: Q3 Earnings Snapshot

Sarepta Therapeutics: Q3 Earnings Snapshot

SRPT : 84.44 (+3.89%)
Why Sarepta Therapeutics Stock Is Crashing Today

There's a plot twist with Sarepta's disappointing clinical results.

SRPT : 84.44 (+3.89%)
Are Gene Therapy Stocks The Market's Next Big Winners?

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

SRPT : 84.44 (+3.89%)
BMRN : 92.42 (+1.47%)
BIIB : 234.64 (+0.24%)
CRSP : 68.65 (+2.88%)
EDIT : 10.77 (+2.28%)
NTLA : 30.84 (+4.08%)
NVS : 98.13 (+0.23%)
ORTX : 16.21 (unch)
REGN : 814.86 (-1.09%)
SLDB : 3.01 (+6.74%)
BLUE : 4.26 (+11.52%)
2 Top Growth Stocks to Buy With $500

No need to break the bank to invest in stocks.

SRPT : 84.44 (+3.89%)
SHOP : 73.86 (+1.43%)
Insiders Are Buying These 2 Stocks

Insider buying in both Loews (NYSE: L) and Sarepta (NASDAQ: SRPT) suggests a positive outlook for these stocks, potentially influencing investor sentiment.

L : 70.01 (-0.40%)
SRPT : 84.44 (+3.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 92.23
2nd Resistance Point 88.37
1st Resistance Point 86.40
Last Price 84.44
1st Support Level 80.57
2nd Support Level 76.71
3rd Support Level 74.74

See More

52-Week High 159.89
Fibonacci 61.8% 119.92
Fibonacci 50% 107.57
Fibonacci 38.2% 95.22
Last Price 84.44
52-Week Low 55.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar